Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has...
-
More than 2,300 cyclists raise a record $12.5M at the Enbridge Tour Alberta for Cancer, fueling life-changing cancer research, treatment and support.
-
First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical development Obrixtamig reaches...
-
STOCKHOLM, June 18, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce that an oral presentation was conducted for the Black Swan Research Initiative’s® (BSRI)...
-
Springfield, Mo., June 10, 2026 (GLOBE NEWSWIRE) -- Fight Colorectal Cancer (Fight CRC) is launching a nationwide call to action: recruit 500 climbers in 30 days for its signature Climb for a Cure...
-
Fortis Life Sciences launches AbNano® VHH Anti-NK Cell Library, the first NK-cell-derived single-domain antibody library for rapid discovery.
-
American Oncology Network Announces Research Studies to be Presented at ASCO 2026 Annual Meeting
-
Artios announces first patient dosed in randomized Phase 2 POLKA study evaluating DNA Polθ inhibitor ART6043 in gBRCA-mutated HER2-negative breast cancer.
-
Not intended for UK and US media Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in treatment-naïve patients1Expedited...
-
Fortis Life Sciences awards Deliver Biosciences the 2026 AbNano® VHH Discovery Grant for in vivo CAR-T, gene therapy & nanoparticle drug delivery research